Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NCT04456673 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

935

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Dupilumab SAR231893
DRUG: Inhaled Corticosteroid
DRUG: Inhaled Long-Acting Beta Agonist
DRUG: Inhaled Long-Acting Muscarinic Antagonist
DRUG: Placebo

Sponsor

Sanofi

Collaborators

[object Object]